This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 28, 2013 /PRNewswire/ -- Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS) a leading IT services, consulting and business solutions organization, announced that it has been designated as a Leader in Life Science Drug Safety Services (DSS) by the prominent global market intelligence firm IDC. Among the attributes that earned TCS its leadership position in the "
IDC MarketScape: Worldwide Life Science Drug Safety Services 2013 Vendor Assessment" (Document # HI239221) are the company's significant industry expertise, strong drug safety IT and KPO delivery capabilities and investment in drug safety specific IP assets.
IDC MarketScape reports are designed to identify factors conducive to success in a particular market, both long term and short term, and then assess vendors participating in the market against these factors. The criteria for each IDC MarketScape report is developed by IDC analysts and can include discussions, surveys and interviews. For this report, the key criteria for defining excellence included: breadth of service offerings, diversity of resources and infrastructure-supporting services delivery, project experience in the Life Sciences DSS outsourcing market, customer service strategy and customer satisfaction, pricing model, go-to-market capabilities and commitment to growth and innovation in the R&D DSS space.
"TCS' large Life Science customer base, broad industry-centric services portfolio, competitive pricing, and strong commitment to growth ensure that the company will continue to be a leading service provider to the industry over both the near and long term," said the report's author,
Alan S. Louie, Ph.D., Research Director, Clinical Development Strategy and Technology, IDC Health Insights.
"For TCS and our Life Sciences customers, patient safety is the absolute priority and we are honored to be listed as a Leader by IDC Health Insights in the Drug Safety market," said
Debashis Ghosh, President, Life Sciences, Manufacturing and Energy at TCS. "This recognition is a testament to our commitment to our customers, of constantly innovating and delivering superior drug safety services, and helping companies in ensuring enhanced care for their patients."
"To be named as a Leader in the Drug Safety Market by IDC Health Insights is indeed a recognition of our differentiated strategy of providing core business services by investing in deep domain expertise and regulatory knowledge. TCS' market leading capabilities in the drug safety space, including adverse event tracking and aggregate reporting, help the pharmaceutical industry meet their compliance requirements more effectively," said
Abid Ali Neemuchwala, Global Head, TCS BPO Services.
TCS' drug safety services help customers enhance efficiency, reduce costs significantly and ensure regulatory compliance. TCS' customers benefit from the company's domain knowledge, global reach, quality systems approach, multi-disciplinary safety expertise and adherence to reporting timelines of the EMEA, FDA, MHRA and other industry authorities.